Option chain shows key data for Tenon Medical's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Tenon Medical.

Tenon Medical (NASDAQ:TNON) Stock, Option Chain

Tenon Medical

Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants, and 3) SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.

Spirit_Airlines-Wikimedia Commons

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGFY

APVO

BIVI

EFSH

GNPX

ALPS ETF Trusthen & Steers Global Realty Majors ETF

JDZG

LGMK

MTEM

NKGN

PHIO

SAVE

SHLS

TNON

VSEE

VSME

VTAK

XPON

ZPTA

Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket

AKAN

CETX

ISRG

JTAI

MGPI

NFLX

NTBL

NUZE

OLMA

ORGS

PEGY

SOBR

STAF

YCBD

Why Intuitive Surgical Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

Nvidia,Logo,On,Mobile,Phone,Screen,Company,Shares,Rise,Or

Exclusives

AAPL

AMZN

APLD

CNEY

GLMD

GOVX

IMRX

INTC

LUMN

LUNR

NDRA

NVDA

PLTR

SMCI

SMMT

TSLA

WHLR

A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar.

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?

Tenon Medical Inc

Northland Capital Markets analyst Nehal Chokshi reiterates Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Market Perform and raises the price target from $350 to $370.

Price Target

Reiteration

Analyst Ratings

PANW

Northland Capital Markets Reiterates Market Perform on Palo Alto Networks, Raises Price Target to $370

Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of an underwritten public offering of 44,964,045 shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 2,235,955 shares of its common stock, and in either case, accompanying Series A warrants to purchase 23,600,000 shares of its common stock at an exercise price of $1.0680 per share of common stock and Series B warrants to purchase 23,600,000 shares of its common stock at an exercise price of $1.3350 per share of common stock, at a combined public offering price of $0.89 per share of common stock and accompanying Series A and Series B warrants (or $0.8899 per pre-funded warrant and accompanying Series A and Series B warrants). All of the securities being sold in the offering are being sold by Verrica. The offering is expected to close on November 22, 2024, subject to the satisfaction of customary closing conditions. Verrica also granted the underwriter an option for a period of 30 days to purchase up to 7,080,000 additional shares of the Company's common stock and/or Series A warrants to purchase up to 3,540,000 additional shares of its common stock and Series B warrants to purchase up to 3,540,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Biotech

Health Care

Financing

Offerings

General

VRCA

Verrica Pharmaceuticals Priced Its Underwritten Public Offering Of $42M At A Combined Public Offering Price Of $0.89/Share And Accompanying Series A And Series B Warrants

D. Boral Capital analyst Jason Kolbert maintains Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) with a Buy and maintains $9 price target.

IVVD

D. Boral Capital Maintains Buy on Invivyd, Maintains $9 Price Target

JMP Securities analyst Trevor Walsh maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Market Outperform and raises the price target from $380 to $415.

JMP Securities Maintains Market Outperform on Palo Alto Networks, Raises Price Target to $415

AMAT

Applied Materials Introduces MAX OLED Solution, A Patented OLED Pixel Architecture And Revolutionary Display Manufacturing Technology

Vestis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) sees FY2025 sales of $2.800 billion-2.830 billion vs $2.85 billion estimate.

Guidance

VSTS

Vestis Sees FY2025 Sales $2.800B-$2.830B vs $2.85B Est

Government

Contracts

ZENA

ZenaTech Has Signed Blue Unmanned Aerial Systems And US National Defense Authorization Act Compliant Partner Agreements For Its Supply Chain To Sell Its ZenaDrone 1000 AI Drone Solutions To US Defense Branches And To NATO Forces

Fiscal 2025 Outlook
As previously announced, CPI's outlook for fiscal 2025 with regard to revenue, net income, Adjusted EBITDA and Adjusted EBITDA Margin is as follows:
<ul>
<li>Revenue in the range of $2.48 billion to $2.58 billion</li>
<li>Net income in the range of $97 million to $113 million</li>
<li>Adjusted EBITDA(1) in the range of $347 million to $377 million</li>
<li>Adjusted EBITDA Margin(1) in the range of 14.0% to 14.6%</li>
</ul>

ROAD

Construction Partners Now Expects FY25 Revenue Of $2.48B-$2.58B (From $2.42B - $2.52B) Vs. Est $2.48B

He will continue to serve as CFO until December 31, 2024 to ensure a smooth transition.
Shyft's Board of Directors is commencing a comprehensive search for a new CFO, supported by a leading, independent executive search firm. The Company is considering both internal and external succession candidates.

Management

SHYF

Shyft Group Says Jon Douyard Has Resigned As CFO To Pursue Another Professional Opportunity Outside The Industry

WIIM

Conduit Pharmaceuticals shares are trading higher after the company announced that the Japan Patent Office granted a composition of matter patent for its lead asset, AZD1656.

This approval follows the recent patent grant in Australia, highlighting Conduit's continued progress in safeguarding its intellectual property portfolio for future out-licensing opportunities.

Conduit Pharmaceuticals Says Japan Patent Office Granted Approval Of A Composition Of Matter Patent Application For Lead Asset AZD1656

Telsey Advisory Group analyst Joseph Feldman maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Outperform and lowers the price target from $195 to $150.

Telsey Advisory Group Maintains Outperform on Target, Lowers Price Target to $150

GXAI

Gaxos.ai Announced That The Company Has Integrated Suno AI And Elevenlabs Into Their Artificial Intelligence Solution For Game Developers And Publishers, Gaxos Labs

IDXX

IDEXX Names Andrew Emerson To Serve As Next CFO, Effective March 1, 2025; Brian McKeon To Retire In June 2025

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and raises the price target from $165 to $190.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Raises Price Target to $190

Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(0.63) by 107.94 percent. The company reported quarterly sales of $1.80 million which missed the analyst consensus estimate of $2.85 million by 36.98 percent. This is a 52.32 percent decrease over sales of $3.77 million the same period last year.

Earnings

EVGN

Evogene Q3 2024 GAAP EPS $(1.31) Misses $(0.63) Estimate, Sales $1.80M Miss $2.85M Estimate

Construction Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROAD#NASDAQ">ROAD</a>) reported quarterly earnings of $0.56 per share which missed the analyst consensus estimate of $0.57 by 1.75 percent. The company reported quarterly sales of $538.163 million which beat the analyst consensus estimate of $538.050 million by 0.02 percent. This is a 13.29 percent increase over sales of $475.026 million the same period last year.

Earnings Beats

Earnings Misses

Construction Partners Q4 2024 GAAP EPS $0.56 Misses $0.57 Estimate, Sales $538.163M Beat $538.050M Estimate

Buybacks

Kyndryl Board Authorizes $300M Share Repurchase Program

TRNR: 81% &#x7C; <a href="https://www.benzinga.com//node/42108368">Interactive Strength Board Approves Maximum Cumulative Bitcoin Purchase Of Up To $5M; Plans To Accept Payment In Digital Currencies</a>
&nbsp;
PYXS: -46% &#x7C; <a href="https://www.benzinga.com//node/42099376">Pyxis Oncology shares are trading higher after the company announced PYX-201 clinical Phase 1 part 1 data.</a>
&nbsp;
WORX: 127% &#x7C; <a href="https://www.benzinga.com//node/42100779">SCWorx Regains Compliance With Nasdaq Stock Market's Continued Listing Requirements Regarding Periodic Reporting</a>

PYXS

TRNR

WORX

Market-Moving News for November 21st

Federal Reserve

Financial Times Reported Earlier, Richmond Fed's Barkin Said Expects Inflation To Continue Dropping Across The US

An update from Tenon Medical, Inc. ( ($TNON) ) is now available. Tenon Medical, Inc. has successfully closed a $4.5 million public offering, manage...

Tenon Medical Secures Funding to Expand Fusion System Operations

IBKR's 25 most actively traded stocks ranked by SA's Quant Metrics

Tenon Medical files to sell 2.4M shares of common stock for holders

Tenon Medical regains compliance with Nasdaq

Tenon Medical (TNON) is in compliance with all relevant Nasdaq continued listing Rules. The Company had previously reported non compliance with Nas...

Tenon Medical regains full compliance with Nasdaq listing rules

Tenon Medical GAAP EPS of -$3.63, revenue of $0.88M misses by $0.38M

Reports Q3 revenue $900K, consensus $1.19M.teve Foster, President and Chief Executive Officer of Tenon Medical (TNON), commented, "During the third...

Tenon Medical reports Q3 EPS ($3.63), consensus ($4.23)

Tenon Medical, Inc. (TNON) Q3 2024 Earnings Call Transcript

Tenon Medical, Inc. ( ($TNON) ) has released its Q3 earnings. Here is a breakdown of the information Tenon Medical, Inc. presented to its investors...

Tenon Medical's Q3 2024 Earnings and Strategic Progress

Maxim lowered the firm's price target on Tenon Medical (TNON) to $8 from $22 but keeps a Buy rating on the shares. The company's Q3 revenue missed ...

Tenon Medical price target lowered to $8 from $22 at Maxim

ASTS

AVGO

GOOGL

MSFT

MSTR

NVDL

ORCL

SOXL

SOXS

SQQQ

TNONW

TQQQ

Press Releases

Tenon(R) Medical Announces the Introduction of the Catamaran(R) SE SI Joint Fusion System

Tenon Medical, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Tenon Medical, Inc. Announces Closing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Tenon Medical Announces Issuance of Three Notices of Allowance for Patent Applications from the USPTO

Tenon Medical(R) Announces Issuance of Three U.S. Patents

Tenon Medical(R) Regains Full Compliance with Nasdaq Continued Listing Requirements

Tenon Medical, Inc. Announces Timing of Third Quarter 2024 Financial Results

Tenon Medical Announces Initial Clinical Cases Successfully Completed with Company's New Catamaran(R) SE SI Joint Fusion System

"The Future is Bright: Peraso Inc. (NASDAQ: PRSO) Expands Technology for Tactical Applications in High-Demand Industries – More Stocks Inside…"

Comments

Tenon Medical

Tenon Medical (TNON) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga